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ARMC5 Variants and Risk of Hypertension in Blacks: MH-GRID Study
Mihail Zilbermint, MD;* Amadou Gaye, PhD;* Annabel Berthon, PhD; Fady Hannah-Shmouni, MD; Fabio R. Faucz, PhD;
Maya B. Lodish, MD, MHSc; Adam R. Davis, PhD; Gary H. Gibbons, MD; Constantine A. Stratakis, MD, D(Med)Sc
Background-—We recently found that ARMC5 variants may be associated with primary aldosteronism in blacks. We investigated a
cohort from the MH-GRID (Minority Health Genomics and Translational Research Bio-Repository Database) and tested the
association between ARMC5 variants and blood pressure in blacks.
Methods and Results-—Whole exome sequencing data of 1377 blacks were analyzed. Target single-variant and gene-based
association analyses of hypertension were performed for ARMC5, and replicated in a subset of 3015 individuals of African descent
from the UK Biobank cohort. Sixteen rare variants were significantly associated with hypertension (P=0.0402) in the gene-based
(optimized sequenced kernel association test) analysis; the 16 and one other, rs116201073, together, showed a strong association
(P=0.0003) with blood pressure in this data set. The presence of the rs116201073 variant was associated with lower blood
pressure. We then used human embryonic kidney 293 and adrenocortical H295R cells transfected with an ARMC5 construct
containing rs116201073 (c.*920T>C). The latter was common in both the discovery (MH-GRID) and replication (UK Biobank) data
and reached statistical significance (P=0.044 [odds ratio, 0.7] and P=0.007 [odds ratio, 0.76], respectively). The allele carrying
rs116201073 increased levels of ARMC5 mRNA, consistent with its protective effect in the epidemiological data.
Conclusions-—ARMC5 shows an association with hypertension in blacks when rare variants within the gene are considered. We
also identified a protective variant of the ARMC5 gene with an effect on ARMC5 expression confirmed in vitro. These results
extend our previous report of ARMC5’s possible involvement in the determination of blood pressure in blacks. ( J Am Heart
Assoc. 2019;8:e012508. DOI: 10.1161/JAHA.119.012508.)
Key Words: adrenocortical adenoma • ARMC5 • black • Conn syndrome • genetics • hypertension • primary aldosteronism
H ypertension is one of the preventable risk factors forcardiovascular disease and death. It is estimated that by
the year 2030, over 23 million Americans will die from
cardiovascular disease.1 According to the Centers for Disease
Control and Prevention, up to 32.5% of Americans older than
20 years have hypertension,2 with varying rates across various
ethnicities. Blacks have a disproportionately increased preva-
lence, earlier age of onset, and greater morbidity related to
hypertension. The National Health and Nutrition Examination
Survey found that 42.1% of non-Hispanic black individuals
have hypertension.3 The predisposition of hypertension in
blacks has been linked to retention of salt and water, either by
excess aldosterone secretion, or to excess sensitivity to
aldosterone, and genetic variants that may result in overac-
tivity of the epithelial sodium channel.4 Nevertheless,
increased risk of hypertension in blacks is likely related to
complex interactions between genetic, behavioral, and social-
environmental determinants that are yet to be determined.
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ORIGINAL RESEARCH
Hyperaldosteronism is associated with insulin resistance,5
diabetes mellitus,6,7 metabolic syndrome,7,8 and cardiovascu-
lar inflammation and fibrosis,9 suggesting that aldosterone
plays an important role in the development of cardiovascular
disease. In young adult blacks, hyperaldosteronism has been
linked to insulin resistance that is independent of age, sex, and
blood pressure (BP).10 Primary aldosteronism (PA) is the most
common cause of endocrine hypertension and leads to
significant morbidity and mortality across all ethnicities. PA is
characterized by an autonomous secretion of aldosterone that
is independent of renin and sodium status, usually attributable
to bilateral adrenocortical hyperplasia. Blacks are more likely to
have PA because of bilateral adrenocortical hyperplasia,4,11–17
although one report suggests a similar prevalence in whites and
blacks.18 Several genetic defects have been identified in PA,
although their link to the increased ethnic predisposition to
hypertension has not been fully studied or understood.
Our group recently found an association between ARMC5
gene variants, predicted to be damaging, in patients with PA
of black descent.19 The ARMC5 gene is a tumor suppressor
implicated in cortisol and/or aldosterone-producing primary
macronodular adrenal hyperplasia, a rare form of endogenous
hypercortisolemia. We identified 12 germline ARMC5 genetic
alterations in 20 unrelated and 2 related individuals (39.3%),
in which all affected patients carrying a variant predicted to be
damaging were black. This study provided the first evidence of
a germline genetic alteration in association with PA specif-
ically for the black population. This genetic association could
in part explain the increased predisposition of blacks to low-
renin hypertension. Recognition of genetic causes of low-renin
hypertension and/or PA and its appropriate treatment may
lead to a significant reduction of morbidity and mortality from
cardiovascular disease in black individiduals.
To date, over 1000 genetic variants contribute to
hypertension, explaining in aggregate 6% of the trait
variance.20–28 However, none of these studies demonstrated
an association with ARMC5. Moreover, investigations of
genetic and transcriptome alterations in black patients with
hypertension is limited.29–31 Several genetic variants have
been described as associated with hypertension32,33 and
compromised arterial elasticity34–36 in blacks.4 Several stud-
ies failed to discover any relationship.37,38 Population-specific
genetic variants, variation in allele frequency, and small
statistical power were among reasons why some of the
genetic loci associated with hypertension lacked the replica-
bility.
Given the paucity of proven genetic drivers of hypertension
in this population at risk, we sought to investigate ARMC5’s
involvement in the regulation of BP among participants in the
MH-GRID (Minority Health Genomics and Translational
Research Bio-Repository Database) study.39
Methods
The data that support the findings of this study are available
from the corresponding author upon request.
MH-GRID Data
The MH-GRID project is a study of hypertension with data
collected across 8 sites in the United States. The data
included in this analysis consist of genotype, from whole
exome sequencing, and phenotype information of self-
identified black men or women aged 30 to 55 years. Cases
are individuals taking ≥2 antihypertensive drugs on a stable
regimen (≥6 months) including a diuretic, and controls are
individuals with optimal BP (≤120/80 mm Hg) without anti-
hypertension medication and with normal kidney function
(estimated glomerular filtration rate >90 mL/min). Patients
with kidney disease, diabetes mellitus, heart failure, HIV, and
liver disease were excluded. More details of inclusion and
exclusion criteria for the MH-GRID are available in Table S1.
UK Biobank Data
The data included in this analysis for the purpose of
replication is from the UK Biobank, a large prospective study
of 502 628 participants recruited between 2006 and 2010.40
The subset used in the replication analysis consists of 3015
participants identified as African. Participants provided their
medical history, medication information, and lifestyle/behav-
ior factors. BP was measured as the mean of 2 sitting systolic
and diastolic BP measurements, taken at baseline using the
Omron HEM-7015IT digital BP monitor (Omron Healthcare).
For the purpose of replication, participants with any form of
cancer were excluded. Cases were defined as individuals with
BP ≥140/90 mm Hg regardless of medication status, and
controls were defined as individuals with optimal BP (≤120/
80 mm Hg) without BP medication. The genetic data are from
the June 2017 release. Details of the design of the arrays and
Clinical Perspective
What Is New?
• Germline variants in ARMC5 may in part be responsible for
regulation of blood pressure in blacks through their in
adrenocortical function.
What Are the Clinical Implications?
• Recognition of hyperaldosteronism and/or its genetics
among blacks may lead to earlier and more effective
treatments that prevent cardiovascular and renal conse-
quences of hypertension in this population.
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quality control have been described elsewhere.40 The partic-
ipants were genotyped on the UK Biobank Axiom array, which
has 805 426 markers. For this analysis, the genotypes were
imputed, via the Michigan Imputation Server,41 using the
“freeze5b” release of the Trans-Omics for Precision Medicine
(TOPMed) whole-genome sequencing data. TOPMed is an
initiative sponsored by the National Heart, Lung, and Blood
Institute of the National Institutes of Health (NIH) and one of
its goals is to achieve ancestral and ethnic diversity and as
such it is currently composed of about 60% of participants
with substantial non-European ancestry. That diversity was
the rationale for the choice of TOPMed as the imputation
platform for this analysis.
GENE-FORECAST Data
Plasma renin activity (PRA) data were not available for the
MH-GRID or UK Biobank data sets included in this analysis.
Therefore, to investigate the relationship between a common
ARMC5 variant and PRA, a smaller data set of 299 samples
was used from the GENE-FORECAST (Genomics, Environmen-
tal Factors and the Social Determinants of Cardiovascular
Disease in African Americans Study). This is a research
platform that establishes a strategic, multiomics systems
biology approach amenable to the deep, multidimensional
characterization of minority health and disease in blacks
(ClinicalTrials.gov identifier: NCT02055209). GENE-FORECAST
is an ongoing study designed to create a cohort established
on a community-based sampling frame of US-born, black men
and women (aged 21–65 years) to be recruited from the
metropolitan Washington, DC, area. GENE-FORECAST sam-
ples were genotyped on a customized Illumina Infinium Multi-
Ethnic Global-8 array platform (Illumina, Inc).
Ethics
The study was approved by the institutional review boards of
Morehouse School of Medicine, Kaiser Permanente, Grady
Health System Research Oversight Committee, and the NIH
(ClinicalTrials.gov identifier: NCT02290392). The institutional
review boards of the Eunice Kennedy Shriver National Institute
of Child Health and Human Development (until 2010) and
National Institute of Diabetes and Digestive and Kidney
Diseases (2010–present) at NIH approved the research for
other protocols (ClinicalTrials.gov identifier: NCT00005927
and NCT00001595). All research participants signed informed
consent.
Genetic Association Analyses
Two analyses were performed using the ARMC5 locus
information from genome-built GRCh37 1: chromosome=16,
start position=3146941, and end position=31478484. Sin-
gle-variant analysis of common variants (minor allele fre-
quency [MAF] ≥0.05) within ARMC5 was conducted in PLINK
1.9.42,43 Gene-based analyses combining common, low
frequency (MAF ≥0.01 and <0.05) and rare variants (MAF
<0.01) within ARMC5 was performed using the optimized
sequence kernel association test (SKAT-O),44 a method
recommended when the genetic architecture of a locus of
interest is not known.45 SKAT-O “collapses” variants into 1
single nucleotide polymorphism set, which is then assigned a
single score used to predict trait values. Quality controls for
the whole exome data are summarized in Figure S1. We used
1377 patients and 44 variants within ARMC5 (3 common, 4
low frequency, and 37 rare variants) for analysis. All of the
association analyses were performed with the genetic
variants treated as an additive and the linear model adjusted
for potential confounders.
Statistical Analysis
Previous work has shown that known heritable traits (eg, body
mass index) can reduce power when included as covariates in
regression models.46–48 Therefore, rather than adjusting
indiscriminately for all of the covariates associated with
hypertension (Table 1), we used the method of Pirinen et al48
to identify the model that maximizes power (ie, the model that
provides the lowest standard error and P value). Our
Table 1. Baseline Characteristics of Patients From the MH-
GRID Study
Characteristics
Cases
(n=623)
Controls
(n=754) P Value
Age, y 48.256.06 43.357.23 1.1791040
Sex
Women, % 57.11 67.18 1.109104
Men, % 42.89 32.82
Current
smoker
(no/yes)
451/165 449/302 2.599107
BMI, kg/m2 33.927.5 28.87.46 1.2591034
SBP 14016 1097 <2.291016
DBP 8910 707 <2.291016
HDL, mg/dL 53.2815.18 55.4216.55 1.459102
LDL, mg/dL 120.0134.57 112.3234.19 5.819105
Triglycerides,
mg/dL
106.9557.04 87.0152.24 8.1091011
BMI indicates body mass index; DBP, diastolic blood pressure; HDL, high-density
lipoprotein; LDL, low-density lipoprotein; MH-GRID, Minority Health Genomics and
Translational Research Bio-Repository Database; SBP, systolic blood pressure.
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preliminary investigations showed that the optimal model is
the one adjusted for age, sex, high-density lipoprotein, low-
density lipoprotein, smoking, and the relevant principal
components (PCs) of the PC analyses (PCA) performed to
investigate admixture.
For MH-GRID, the PCA results show that PC1 separates the
2 main continental ancestries (West African and European) of
blacks (Figure S2). Thus, PC1 was added to the model to
adjust for global ancestry.
We chose the “African” subset that had MAFs similar to
those observed in MH-GRID for the replicated loci. This was
done to avoid population stratification, which decreases
statistical power. For UK Biobank, the PCA results show, since
the analysis was restricted to the African subset, PC2 and
PC3, which account for admixture in the African populations
were added to the model to adjust for global ancestry
(Figure S3).
Molecular Analysis
The DNA sequence of ARMC5-203 isoform (NM_024742) was
cloned in pUCminusMCS plasmid (Blue Heron). The
rs116201073 (c.*920T>C) DNA change was introduced by
targeted mutagenesis following the manufacturer’s instruc-
tions (200555-12, Agilent Technologies UK Ltd).
Human embryonic kidney 293 (HEK293) cells were grown
in Dulbecco’s modified Eagle medium (DMEM) (11995,
Gibco) enriched with 10% fetal bovine serum (FBS) (900,
Gemini Bio-Products Inc), GlutaMAX (35050, Gibco), and Anti
(15240, Gibco), whereas human adrenocarcinoma (H295R)
cells were maintained in DMEM-F12 (11320, Gibco) contain-
ing 10% FBS (900, Gemini Bio-Products Inc), GlutaMAX
(35050, Gibco), Anti (15240, Gibco), and Insulin-Transferrin-
Selenium (41400, Thermo Fisher Scientific). A total of
300 000 HEK293 or 400 000 H295R cells were seeded in
a well of 6-well plate and were transfected the next day with
1 lg of empty, wild-type or mutant plasmid using Lipofec-
tamine LTX (15338100, Thermo Fisher Scientific) or
Effectene (301425, Qiagen), respectively. Where indicated,
cells were treated with 10 ng of cycloheximide (C4859,
Sigma-Aldrich) or DMSO (34869, Sigma-Aldrich) for the
control for 1, 2, or 3 hours before collection. Cells were
harvested in Trizol (15596018, Ambion, Inc) 48 hours after
transfection for RNA extraction following the manufacturer’s
protocol. Five hundred thousand nanograms of RNA were
then reverse transcribed (11753-050, Thermo Fisher Scien-
tific) as indicated in the manufacturer’s instructions. One
microliter of a one-twentieth dilution of cDNA was amplified
by quantitative polymerase chain reaction conducted with
SybrGreen (4364344, Thermo Fisher Scientific). The primers
used to analyze ARMC5, ARMC5-203 expression were
previously described.49
Results
Demographics
The baseline characteristics of the 1377 individuals who
passed quality controls are reported in Table 1. The hyper-
tensive group was older and contained more men and had a
larger body mass index. The proportion of smokers was higher
in the control group and lipid profiles were better (lower low-
density lipoprotein and triglycerides and higher high-density
lipoprotein) in the control group. The strong association
between BP pressure (systolic BP and diastolic BP) and
hypertension reported in Table 1 is attributable to the design
of MH-GRID, which focused on the tails of hypertension
distribution (controls with optimal BP versus cases taking ≥2
BP medications).
Single-Variant Analysis
In the discovery analysis (MH-GRID data), ARMC5 variant
rs116201073 reached nominal significance (P=0.044; odds
ratio, 0.7), suggesting a protective effect for this variant
(Table 2). For the replication analysis (GENE-FORECAST data),
the variant rs116201073 was imputed with high confidence
(R2=0.96) and its MAF (0.077) was similar to what was
observed in MH-GRID. For the results presented in Table 2,
the association, in UK Biobank, was adjusted for age, sex,
smoking, alcohol, and PC2 and PC3. The other variables we
adjusted for in MH-GRID were not available in UK Biobank.
Gene-Based Analysis
Discovery (MH-GRID)
The gene-based analysis was adjusted for the same covariates
as in the single-variant analysis and conducted by combining
all 37 rare variants and then applying conditional analysis in
SKAT-O to sift out noise variants50 and identify the variants
that truly contribute to the effect (ie, those that decrease the
P value of the association). That process identified 16 rare
variants that together are associated with hypertension
(P=0.0011). SKAT-O of a set that consists of those 16
variants and the common variant identified in the single-
variant analysis was more strongly associated with hyperten-
sion (Table 3). Subsequent SKAT-O analyses considering low-
frequency variants alone or in combination with the rare
variants were not conclusive. The SKAT-O results for MH-GRID
are summarized in Table S2.
All of the 16 rare variants associated with hypertension in
the SKAT-O and outlined in Table 4 have the same effect as
the common variant rs116201073 and this explains the
stronger association for the set of 17 (16 rare+1 common).
Figure 1 reports the number of mutant alleles across the 16
rare variants by cases and control. Across the 1377
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individuals, only 17 were heterozygous and 1 was homozy-
gous for the mutant allele and all are controls.
Table 4 lists the 17 variants. Seven of the 16 rare variants
have been previously reported while the remainder, along with
4 of 7 variants known as rare and nonsynonymous, are novel
from the MH-GRID exome data. Overall, 6 variants, including
the common single nucleotide polymorphism, exhibit evi-
dence of selective constraint as computed by 2 mammalian
conservation algorithms, the Genomic Evolutionary Rate
Profiling51 and SiPhy,52 as reported in the HaploReg v4.1
database.53
Replication (UK Biobank)
Because of the known challenge of imputing rare variants,
only 4 of the 16 rare could be imputed and 2 of those were
monomorphic in the UK Biobank data. Therefore, SKAT-O
replication was attempted with 2 rare variants imputed with
respective R2 values of 0.92 (rs367810854. MAF=0.0008 in
UK Biobank) and 0.67 (rs141923065, MAF=0.0012 in UK
Biobank). The results of the gene-based analysis with the 3
variants, adjusted for age, sex, smoking, and alcohol, was
significant in UK Biobank (P=0.0083). The frequency of the
replicated variants in various populations is reported in
Table S3.
The common variant rs116201073 seems to be specific to
Africans, where it is present only in Africans or African-
admixed populations included in the 1000 Genomes Project
(Table 4). In the TOPMed data available from the BRAVO
portal (University of Michigan), specific allele frequency are
not available for some minority populations and the same info
as in the 1000 Genomes Project. In the Genome Aggregation
Database (gnomAD), the frequencies reported are 0.075 for
African, 0.002 for Latino, 0.002 for “other,” and essentially 0
(<0.00001) for the other populations.
As for the rare variants included in the replication analysis,
in the 1000 Genomes Project: rs141923065 is observed only
in African-Caribbean in Barbados, African American from the
Southwest (ASW), and Han Chinese. Intriguingly, rs367810854
is observed only in South Asian populations (gnomAD provides
similar information with 0.0499 for the category “South Asian”
and <0.0001 or other continental populations). Additional
details are available in Table S3.
ARMC5 Variant rs116201073 and PRA
First, we evaluated the relationship between hypertension and
PRA across the 299 samples (115 with hypertension versus
184 controls). The results showed lower PRA in the hyper-
tensive group (mean=1.40 ng/mL per hour in patients with
hypertension versus 2.04 ng/mL per hour in controls), but
the difference was not statistically significant (t statis-
tic=1.50, P=0.13 [95% CI, 0.20 to 1.47]). Then we estimated
the association between the variant and PRA dichotomized
using a cutoff of 0.65 ng/mL per hour54 to have, respectively,
82 and 134 patients in the low and high renin groups across
the 216 samples for which genotype data were available in
GENE-FORECAST. The variant was less frequent in the low
renin group (6% versus 7% in the rest of the sample); however,
Table 2. Single-Variant Analysis Results and Details of the SNPs
Variant
MH-GRID Study UK Biobank
rs116201073 rs11863886 rs11150624 rs116201073
Position on chromosome 16 31477442 31477460 31476458 31477442
Alleles (minor/major) Cytosine/thymine Adenine/guanine Thymine/cytosine Cytosine/thymine
MAF 0.071 0.182 0.096 0.077
OR 0.7 1.21 1.08 0.76
SD 0.18 0.11 0.14 0.1
P value 0.044 0.089 0.580 0.0068
Frequency in cases, % 5.50 18.70 10.10 7.61
Frequency in controls, % 8.20 16.90 9.50 8.85
Functional information Synonymous Synonymous Missense Synonymous
MAF indicates minor allele frequency; MH-GRID, Minority Health Genomics and Translational Research Bio-Repository Database; OR, odds ratio; SNP, single nucleotide polymorphism.
Table 3. SKAT-O Gene-Based Analysis Results
Variant P Value No. of Variants Collapsed
Rare variants 0.0011 16
Rare variants+rs116201073 0.0003 17
SKAT-O indicates optimized sequence kernel association test.
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the association was not statistically significant (odds ratio,
0.87; P>0.05).
Effect of ARMC5 Variant, rs116201073
The rs116201073 variant is a synonymous variant in most of
the ARMC5 isoforms except in the NM_024742 isoform
(referred to as ARMC5-203 in the Ensembl database) in which
it is located in the 30-untranslated transcribed region (UTR). To
determine its potential effect on ARMC5’s expression, we
transfected wild-type and mutant ARMC5-203 plasmids in
HEK293 cells and analyzed ARMC5 presence by real-time
quantitative polymerase chain reaction, 24 and 48 hours after
transfection. Whereas at 24 hours, no difference was
observed between the 2 groups, at 48 hours, there was a
significant increase in ARMC5 mRNA accumulation when
ARMC5 carried the variant allele (Figure 2).
Similar results were obtained using either primers
targeting all ARMC5 isoforms (Figure 2A) or specifically
the ARMC5-203 isoform that was overexpressed (Figure 2B).
The treatment of the transfected cells with a translation
inhibitor, cycloheximide, for 2 or 3 hours before collection
led to a normalization of the ratio of ARMC5-203 mutant
and wild-type mRNA demonstrating that the elevation of
mutant ARMC5 mRNA was the result of a decrease of its
translation rate. A similar elevation of ARMC5-203 mRNA
was found at 48 and 72 hours after transfection in an
adrenocortical cell line H295R, but this increase was not
significant (Figure S4).
Discussion
Analysis of our data identified one common variant
(rs116201073) located in the 30UTR end of the ARMC5 gene
that was associated with decreased risk of hypertension (odds
ratio, 0.7) in a sample set of 1377 blacks from the MH-GRID
study. That single-variant association was replicated with a
smaller P value in a UK Biobank sample set of 3015 African
participants. Gene-based SKAT-O analysis, in MH-GRID, also
revealed a set of 16 rare variants associated with hyperten-
sion in blacks with the same protective effect as the common
variant rs116201073. Together, these 16 rare and 1 common
variant (a set of 17 variants) were significantly associated with
BP in a subsequent gene-based test. The gene-based results
were also replicated in the UK Biobank data with the rare
variants that could be imputed. These results confirm our
previous report of ARMC5’s possible involvement in regulating
BP in blacks, possibly as a result of its role in determining the
presence of bilateral adrenocortical hyperplasia and/or
hyperaldosteronism.19
Table 4. List of the Set of 17 Variants Significantly Associated With Hypertension and MAF in the MH-GRID Study
Variant POS (GRCh37) MAF Functional Information (dbSNP) Under Selection (GERP/SiPhy)
16:31473335 31473335 0.0004
16:31473823 31473823 0.0004
rs141923065 31474091 0.0004 Missense (glutamine ⇒ arginine) Yes
16:31474095 31474095 0.0007
rs202103062 31476361 0.0004 Missense (glycine ⇒ cysteine) No
rs370836071 31477234 0.0004 Missense (threonine ⇒ methionine)
16:31477236 31477236 0.0004
rs116201073 31477442 0.0711 Synonymous Yes
16:31477452 31477452 0.0004
16:31477486 31477486 0.0004
16:31477569 31477569 0.0004
16:31477574 31477574 0.0004
rs181967284 31477834 0.0004 Missense (arginine ⇒ glutamine) Yes
rs367810854 31477859 0.0004 Synonymous
rs372567714 31477945 0.0004 Missense (glutamic acid ⇒ valine)
16:31478013 31478013 0.0004
rs61734240 31478192 0.0004 Synonymous Yes
MAF indicates minor allele frequency; MH-GRID, Minority Health Genomics and Translational Research Bio-Repository Database; POS, position; GRCh37, Genome Reference Consortium
Human Build 37; dbSNP, The Single Nucleotide Polymorphism Database; GERP, Genomic Evolutionary Rate Profiling; SiPhy, SIte-specific PHYlogenetic analysis.
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The ARMC5 gene is a putative tumor suppressor that is
located on chromosome 16p11.2 and belongs to the family of
armadillo-repeat–containing proteins.55,56 In humans, ARMC5
consists of 8 exons and has an unknown function,19,49
although recent evidence suggests that it plays a critical role
for fetal development and immune responses through inter-
actions with proteins from different pathways.57,58 Four
ARMC5 isoforms exist, with a different pattern of expression,
although all 4 are expressed in the adrenal glands.55 The
ARMC5 gene has been recently implicated in endogenous
hypercortisolemia due to primary macronodular adrenal
hyperplasia,59–64 which is characterized by multiple nodules
(>1 cm) in the adrenal cortex and hypercortisolemia.19
Biallelic inactivation of ARMC5 (germline and somatic) is
required for the development of adrenocortical hyperplasia,
which is consistent with the 2-hit hypothesis of tumorigen-
esis.59 Most disease-causing variants in ARMC5 are frame-
shift and/or nonsense, and lead to loss of function of the
gene.62 Overexpression of ARMC5 in adrenocortical carci-
noma cell line H295R leads to increased cell death,59 while
silencing of the gene in nonmutated primary macronodular
adrenal hyperplasia cell cultures leads to a decrease of
apoptosis.65
Genetic variants in ARMC5 have rarely been implicated in
PA. The largest study to date examined 56 patients with PA
and found 12 different germline variants in ARMC5 (6
predicted to be damaging by in silico analysis) in 20 unrelated
and 2 related individuals (39%).19 These variants were
exclusively found in black individuals and silencing of ARMC5
in H295R cells decreased CYP11B2 expression.19
A recent study in a different cohort of patients with PA
reported 18 ARMC5 variants (5 rare with an allele frequency
<1%) and 2 new variants that were not predicted to be
damaging.66 Variants in ARMC5 are difficult to identify as
pathogenic because ARMC5’s function remains unclear;
however, some missense variants fail to induce apoptosis
after transfection in a human adrenocortical cancer cell line
H295R.59 Although the link between ARMC5 and PA is yet to
be explained, our data support a potential link between
ARMC5 variants and hypertension in people of African
descent.
PRA and aldosterone are often used as a screening test for
PA. We studied possible associations between PRA and
hypertension in patients from the GENE-FORECAST study.
Although these results were not significant, perhaps because
of small sample size, the directions of the relationships were
consistent with the seemingly protective effect of the variant
(rs116201073) reported in the genetic associations’ analyses
of MH-GRID and UK Biobank data sets.
Interestingly, the rs116201073 variant seems to be specific
to the African population with the C allele present only in
African and African admixed populations included in the 1000
Genomes Project. Given the significantly higher prevalence of
the variant in the control we can hypothesize that either the
Figure 1. Number of mutant alleles by cases and controls across the Minority Health Genomics and
Translational Research Bio-Repository Database. sHTN indicates severe hypertension.
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minor C allele has a direct protective effect against hyperten-
sion in this population predisposed to low-renin hypertension
or this variant is a genetic marker of a protector factor. This
variant predicted to be benign is synonymous in 3 ARMC5
isoforms: ARMC5-201, ARMC5-202, and ARMC5-205. In the
ARMC5-203 isoform, which is ubiquitously expressed49 and
even overexpressed in our hypertensive cohort compared with
controls, the rs116201073 variant is located in the 30-UTR. The
30-UTR region is essential for the regulation of mRNA stability,
expression, and localization.67 Indeed, our in vitro experiments
in HEK293 cells demonstrate that the ARMC5-203 carrying the
variant mRNA is accumulated compared with the wild-type
mRNA and this is the result, at least in part, of a reduction in its
translation rate.
ARMC5-203 function has not yet been studied but it is
noteworthy that it is the only protein isoform that has the
Armadillo domain but not the BTB (BR-C, ttk, and bab)/POZ
(Pox virus and Zinc finger) domain. This suggests a specific
and nonredundant role between this isoform and the 3 other
ARMC5 isoforms.49 Altogether, these data suggest that the
ARMC5-203 protein would promote hypertension, as the
variant decreasing its protein translation is protective against
hypertension.
Predisposition to low-renin hypertension in blacks has been
broadly studied. Part of this predisposition is attributed to the
activation of the renin-angiotensin-aldosterone system by its
promotion of sodium retention.4,68 It could be explained by
genetic variants that predispose to inappropriate secretion of
aldosterone, or genetic variants that affect the epithelial sodium
channel (eg, Liddle syndromephenotype), ultimately resulting in
water preservation.4,69 The following genetic variants were
found to predispose to PA and/or inappropriate secretion of
aldosterone: CYP11B2, KCNJ5, ATP1A1, ATP2B3, CACNA1D,
and ARMC5.19,70–72 The Liddle syndrome phenotype could be
caused by GRK, NEDD4L, CYP4A11, NPPA, UMOD, and perhaps
other, yet to be discovered genetic variants.4,70,73
Why do people of African origin have more hypertension
than foreign-born Africans in the United States? It is possible,
that natural selection for salt and water retention created a
survival advantage for people transported across the Atlantic
Ocean in hot conditions. This phenomenon is known as the
African Diaspora hypothesis.4,74–76
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Figure 2. Comparison of wild-type (WT) and mutant ARMC5 (rs116201073) expression in human
embryonic kidney 293 (HEK293) cell line. A and B, Real-time quantitative polymerase chain reaction
(RTqPCR) using primers recognizing all ARMC5 isoforms (A) or only the ARMC5-203 isoform (B) on HEK293
cells transfected with WT or mutant (variant-carrying) ARMC5-203 plasmid for 24 and 48 hours. C, The ratio
of the mutant and the WT ARMC5-203 expression detected by RTqPCR on HEK293 cells untreated or
treated 1, 2, or 3 hours with a translation blocker, cycloheximide. The graph represents the means of at
least 3 independent experimentsstandard error of the mean (SEM).
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Study Limitations
Our study has limitations and should be interpreted with
caution. First, the MH-GRID hypertensive case definition was
based on hypertension diagnosis by a clinician and the
participant being prescribed ≥2 antihypertensive medications
for at least 6 months before enrollment into the study. The
available UK Biobank data set did not have information about
the number of antihypertensive medications that the study
participants were taking, as the cases were defined as those
with hypertension diagnosed by a clinician regardless of
medication status and/or those with average BP ≥140/
90 mm Hg across several measures at the visit;. Second, a
“healthy volunteer” effect was demonstrated in the UK
Biobank study,77 thus generalization of the present study is
likely limited. Third, we do not have information about the
duration of antihypertensive therapy, and it is possible that
the duration of medication use may be considered to be a
proxy for disease severity. Fourth, we have limited data on the
biochemical phenotype of the participants: the association
between the common genetic variant and low renin could not
be reliably established because of the small sample. Fifth, we
do not know whether patients had the Liddle syndrome
phenotype (low renin and low aldosterone) or PA (low renin
and high aldosterone). Finally, we did not consider other
variants/loci of interest for an additive effect on hypertension.
Conclusions
We identified one common variant (rs116201073) of the
ARMC5 gene that was associated with a decreased risk of
hypertension in blacks and a set of 16 rare variants associated
with hypertension. These results extend our previous report of
germline ARMC5 variants that may be linked to hypertension in
blacks. Although not conclusive, the evaluation of the main
variant with respect to PRA may suggest a link to low-renin
hypertension. Further genetic and molecular studies are
needed to confirm and complement these findings.
Acknowledgments
We thank Diane Cooper, MSLS, NIH Library, for providing assistance
in writing this article. We thank patients and researchers from the
MH-GRID Network.
Sources of Funding
This research was supported in part by the Intramural Research
Program of Eunice Kennedy Shriver National Institute of Child
Health and Human Development, NIH Grant Z1A HD008920-08
to Constantine A. Stratakis. Grant 1RC4MD005964-0 to Gary
Gibbons.
Disclosures
None.
References
1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de
Ferranti S, Despres JP, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela
BM, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB,
McGuire DK, Mohler ER III, Moy CS, Muntner P, Mussolino ME, Nasir K,
Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ,
Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Willey JZ, Woo D, Yeh RW,
Turner MB; American Heart Association Statistics Committee and Stroke
Statistics Subcommittee. Heart disease and stroke statistics—2015 update: a
report from the American Heart Association. Circulation. 2015;131:e29–e322.
2. Statistics NCfH. Health, United States, 2014: selected health conditions and
risk factors, by age: United States, selected years 1988–1994 through 2011–
2012. 2014.
3. Nwankwo T, Yoon SS, Burt V, Gu Q. Hypertension among adults in the United
States: National Health and Nutrition Examination Survey, 2011–2012. NCHS
Data Brief. 2013;(133):1–8.
4. Spence JD, Rayner BL. Hypertension in blacks: individualized therapy based on
renin/aldosterone phenotyping. Hypertension. 2018;72:263–269.
5. Garg R, Hurwitz S, Williams GH, Hopkins PN, Adler GK. Aldosterone production
and insulin resistance in healthy adults. J Clin Endocrinol Metab.
2010;95:1986–1990.
6. Wu VC, Chueh SJ, Chen L, Chang CH, Hu YH, Lin YH, Wu KD, Yang WS; TAIPAI
Study Group. Risk of new-onset diabetes mellitus in primary aldosteronism: a
population study over 5 years. J Hypertens. 2017;35:1698–1708.
7. Hanslik G, Wallaschofski H, Dietz A, Riester A, Reincke M, Allolio B, Lang K,
Quack I, Rump LC, Willenberg HS, Beuschlein F, Quinkler M, Hannemann A;
Participants of the German Conn’s Registry. Increased prevalence of diabetes
mellitus and the metabolic syndrome in patients with primary aldosteronism of
the German Conn’s Registry. Eur J Endocrinol. 2015;173:665–675.
8. Bochud M, Nussberger J, Bovet P, Maillard MR, Elston RC, Paccaud F,
Shamlaye C, Burnier M. Plasma aldosterone is independently associated with
the metabolic syndrome. Hypertension. 2006;48:239–245.
9. de Rita O, Hackam DG, Spence JD. Effects of aldosterone on human
atherosclerosis: plasma aldosterone and progression of carotid plaque. Can J
Cardiol. 2012;28:706–711.
10. Huan Y, Deloach S, Keith SW, Goodfriend TL, Falkner B. Aldosterone and
aldosterone: renin ratio associations with insulin resistance and blood
pressure in African Americans. J Am Soc Hypertens. 2012;6:56–65.
11. Spence JD. The current epidemic of primary aldosteronism: causes and
consequences. J Hypertens. 2004;22:2038–2039; author reply 2039.
12. Russell RP, Masi AT. The prevalence of adrenal cortical hyperplasia at autopsy
and its association with hypertension. Ann Intern Med. 1970;73:195–205.
13. Russell RP, Masi AT, Richter ED. Adrenal cortical adenomas and hypertension.
A clinical pathologic analysis of 690 cases with matched controls and a review
of the literature. Medicine (Baltimore). 1972;51:211–225.
14. Russell RP, Masi AT. Significant associations of adrenal cortical abnormalities
with “essential” hypertension. Am J Med. 1973;54:44–51.
15. Kidambi S, Kotchen JM, Grim CE, Raff H, Mao J, Singh RJ, Kotchen TA.
Association of adrenal steroids with hypertension and the metabolic syndrome
in blacks. Hypertension. 2007;49:704–711.
16. Spence JD. Physiologic tailoring of therapy for resistant hypertension:
20 years’ experience with stimulated renin profiling. Am J Hypertens.
1999;12:1077–1083.
17. Tu W, Eckert GJ, Hannon TS, Liu H, Pratt LM, Wagner MA, Dimeglio LA, Jung J,
Pratt JH. Racial differences in sensitivity of blood pressure to aldosterone.
Hypertension. 2014;63:1212–1218.
18. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperal-
dosteronism among black and white subjects with resistant hypertension.
Hypertension. 2002;40:892–896.
19. Zilbermint M, Xekouki P, Faucz FR, Berthon A, Gkourogianni A, Schernthaner-
Reiter MH, Batsis M, Sinaii N, Quezado MM, Merino M, Hodes A, Abraham SB,
Libe R, Assie G, Espiard S, Drougat L, Ragazzon B, Davis A, Gebreab SY, Neff R,
Kebebew E, Bertherat J, Lodish MB, Stratakis CA. Primary aldosteronism and
ARMC5 variants. J Clin Endocrinol Metab. 2015;100:E900–E909.
20. Evangelou E, Warren HR, Mosen-Ansorena D, Mifsud B, Pazoki R, Gao H,
Ntritsos G, Dimou N, Cabrera CP, Karaman I, Ng FL, Evangelou M, Witkowska
K, Tzanis E, Hellwege JN, Giri A, Velez Edwards DR, Sun YV, Cho K, Gaziano JM,
DOI: 10.1161/JAHA.119.012508 Journal of the American Heart Association 9
ARMC5 and Hypertension in Blacks Zilbermint et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
Wilson PWF, Tsao PS, Kovesdy CP, Esko T, Magi R, Milani L, Almgren P, Boutin
T, Debette S, Ding J, Giulianini F, Holliday EG, Jackson AU, Li-Gao R, Lin WY,
Luan J, Mangino M, Oldmeadow C, Prins BP, Qian Y, Sargurupremraj M, Shah
N, Surendran P, Theriault S, Verweij N, Willems SM, Zhao JH, Amouyel P,
Connell J, de Mutsert R, Doney ASF, Farrall M, Menni C, Morris AD, Noordam
R, Pare G, Poulter NR, Shields DC, Stanton A, Thom S, Abecasis G, Amin N,
Arking DE, Ayers KL, Barbieri CM, Batini C, Bis JC, Blake T, Bochud M, Boehnke
M, Boerwinkle E, Boomsma DI, Bottinger EP, Braund PS, Brumat M, Campbell
A, Campbell H, Chakravarti A, Chambers JC, Chauhan G, Ciullo M, Cocca M,
Collins F, Cordell HJ, Davies G, Borst MH, Geus EJ, Deary IJ, Deelen J, Del Greco
MF, Demirkale CY, Dorr M, Ehret GB, Elosua R, Enroth S, Erzurumluoglu AM,
Ferreira T, Franberg M, Franco OH, Gandin I, Gasparini P, Giedraitis V, Gieger
C, Girotto G, Goel A, Gow AJ, Gudnason V, Guo X, Gyllensten U, Hamsten A,
Harris TB, Harris SE, Hartman CA, Havulinna AS, Hicks AA, Hofer E, Hofman A,
Hottenga JJ, Huffman JE, Hwang SJ, Ingelsson E, James A, Jansen R, Jarvelin
MR, Joehanes R, Johansson A, Johnson AD, Joshi PK, Jousilahti P, Jukema JW,
Jula A, Kahonen M, Kathiresan S, Keavney BD, Khaw KT, Knekt P, Knight J,
Kolcic I, Kooner JS, Koskinen S, Kristiansson K, Kutalik Z, Laan M, Larson M,
Launer LJ, Lehne B, Lehtimaki T, Liewald DCM, Lin L, Lind L, Lindgren CM, Liu
Y, Loos RJF, Lopez LM, Lu Y, Lyytikainen LP, Mahajan A, Mamasoula C,
Marrugat J, Marten J, Milaneschi Y, Morgan A, Morris AP, Morrison AC, Munson
PJ, Nalls MA, Nandakumar P, Nelson CP, Niiranen T, Nolte IM, Nutile T,
Oldehinkel AJ, Oostra BA, O’Reilly PF, Org E, Padmanabhan S, Palmas W,
Palotie A, Pattie A, Penninx B, Perola M, Peters A, Polasek O, Pramstaller PP,
Nguyen QT, Raitakari OT, Ren M, Rettig R, Rice K, Ridker PM, Ried JS, Riese H,
Ripatti S, Robino A, Rose LM, Rotter JI, Rudan I, Ruggiero D, Saba Y, Sala CF,
Salomaa V, Samani NJ, Sarin AP, Schmidt R, Schmidt H, Shrine N, Siscovick D,
Smith AV, Snieder H, Sober S, Sorice R, Starr JM, Stott DJ, Strachan DP,
Strawbridge RJ, Sundstrom J, Swertz MA, Taylor KD, Teumer A, Tobin MD,
Tomaszewski M, Toniolo D, Traglia M, Trompet S, Tuomilehto J, Tzourio C,
Uitterlinden AG, Vaez A, van der Most PJ, van Duijn CM, Vergnaud AC,
Verwoert GC, Vitart V, Volker U, Vollenweider P, Vuckovic D, Watkins H, Wild
SH, Willemsen G, Wilson JF, Wright AF, Yao J, Zemunik T, Zhang W, Attia JR,
Butterworth AS, Chasman DI, Conen D, Cucca F, Danesh J, Hayward C,
Howson JMM, Laakso M, Lakatta EG, Langenberg C, Melander O, Mook-
Kanamori DO, Palmer CNA, Risch L, Scott RA, Scott RJ, Sever P, Spector TD,
van der Harst P, Wareham NJ, Zeggini E, Levy D, Munroe PB, Newton-Cheh C,
Brown MJ, Metspalu A, Hung AM, O’Donnell CJ, Edwards TL, Million Veteran
Program, Psaty BM, Tzoulaki I, Barnes MR, Wain LV, Elliott P, Caulfield MJ.
Genetic analysis of over 1 million people identifies 535 new loci associated
with blood pressure traits. Nat Genet. 2018;50:1412–1425.
21. Cabrera CP, Ng FL, Warren HR, Barnes MR, Munroe PB, Caulfield MJ. Exploring
hypertension genome-wide association studies findings and impact on
pathophysiology, pathways, and pharmacogenetics. Wiley Interdiscip Rev Syst
Biol Med. 2015;7:73–90.
22. Ehret GB, Ferreira T, Chasman DI, Jackson AU, Schmidt EM, Johnson T,
Thorleifsson G, Luan J, Donnelly LA, Kanoni S, Petersen AK, Pihur V,
Strawbridge RJ, Shungin D, Hughes MF, Meirelles O, Kaakinen M, Bouatia-Naji
N, Kristiansson K, Shah S, Kleber ME, Guo X, Lyytikainen LP, Fava C, Eriksson
N, Nolte IM, Magnusson PK, Salfati EL, Rallidis LS, Theusch E, Smith AJP,
Folkersen L, Witkowska K, Pers TH, Joehanes R, Kim SK, Lataniotis L, Jansen R,
Johnson AD, Warren H, Kim YJ, Zhao W, Wu Y, Tayo BO, Bochud M; Consortium
CH-E, Consortium C-H, Wellcome Trust Case Control C, Absher D, Adair LS,
Amin N, Arking DE, Axelsson T, Baldassarre D, Balkau B, Bandinelli S, Barnes
MR, Barroso I, Bevan S, Bis JC, Bjornsdottir G, Boehnke M, Boerwinkle E,
Bonnycastle LL, Boomsma DI, Bornstein SR, Brown MJ, Burnier M, Cabrera CP,
Chambers JC, Chang IS, Cheng CY, Chines PS, Chung RH, Collins FS, Connell
JM, Doring A, Dallongeville J, Danesh J, de Faire U, Delgado G, Dominiczak AF,
Doney ASF, Drenos F, Edkins S, Eicher JD, Elosua R, Enroth S, Erdmann J,
Eriksson P, Esko T, Evangelou E, Evans A, Fall T, Farrall M, Felix JF, Ferrieres J,
Ferrucci L, Fornage M, Forrester T, Franceschini N, Duran OHF, Franco-
Cereceda A, Fraser RM, Ganesh SK, Gao H, Gertow K, Gianfagna F, Gigante B,
Giulianini F, Goel A, Goodall AH, Goodarzi MO, Gorski M, Grassler J, Groves C,
Gudnason V, Gyllensten U, Hallmans G, Hartikainen AL, Hassinen M, Havulinna
AS, Hayward C, Hercberg S, Herzig KH, Hicks AA, Hingorani AD, Hirschhorn JN,
Hofman A, Holmen J, Holmen OL, Hottenga JJ, Howard P, Hsiung CA, Hunt SC,
Ikram MA, Illig T, Iribarren C, Jensen RA, Kahonen M, Kang H, Kathiresan S,
Keating BJ, Khaw KT, Kim YK, Kim E, Kivimaki M, Klopp N, Kolovou G,
Komulainen P, Kooner JS, Kosova G, Krauss RM, Kuh D, Kutalik Z, Kuusisto J,
Kvaloy K, Lakka TA, Lee NR, Lee IT, Lee WJ, Levy D, Li X, Liang KW, Lin H, Lin L,
Lindstrom J, Lobbens S, Mannisto S, Muller G, Muller-Nurasyid M, Mach F,
Markus HS, Marouli E, McCarthy MI, McKenzie CA, Meneton P, Menni C,
Metspalu A, Mijatovic V, Moilanen L, Montasser ME, Morris AD, Morrison AC,
Mulas A, Nagaraja R, Narisu N, Nikus K, O’Donnell CJ, O’Reilly PF, Ong KK,
Paccaud F, Palmer CD, Parsa A, Pedersen NL, Penninx BW, Perola M, Peters A,
Poulter N, Pramstaller PP, Psaty BM, Quertermous T, Rao DC, Rasheed A,
Rayner N, Renstrom F, Rettig R, Rice KM, Roberts R, Rose LM, Rossouw J,
Samani NJ, Sanna S, Saramies J, Schunkert H, Sebert S, Sheu WH, Shin YA,
Sim X, Smit JH, Smith AV, Sosa MX, Spector TD, Stancakova A, Stanton A,
Stirrups KE, Stringham HM, Sundstrom J, Swift AJ, Syvanen AC, Tai ES, Tanaka
T, Tarasov KV, Teumer A, Thorsteinsdottir U, Tobin MD, Tremoli E, Uitterlinden
AG, Uusitupa M, Vaez A, Vaidya D, van Duijn CM, van Iperen EPA, Vasan RS,
Verwoert GC, Virtamo J, Vitart V, Voight BF, Vollenweider P, Wagner A, Wain
LV, Wareham NJ, Watkins H, Weder AB, Westra HJ, Wilks R, Wilsgaard T, Wilson
JF, Wong TY, Yang TP, Yao J, Yengo L, Zhang W, Zhao JH, Zhu X, Bovet P,
Cooper RS, Mohlke KL, Saleheen D, Lee JY, Elliott P, Gierman HJ, Willer CJ,
Franke L, Hovingh GK, Taylor KD, Dedoussis G, Sever P, Wong A, Lind L,
Assimes TL, Njolstad I, Schwarz PE, Langenberg C, Snieder H, Caulfield MJ,
Melander O, Laakso M, Saltevo J, Rauramaa R, Tuomilehto J, Ingelsson E,
Lehtimaki T, Hveem K, Palmas W, Marz W, Kumari M, Salomaa V, Chen YI,
Rotter JI, Froguel P, Jarvelin MR, Lakatta EG, Kuulasmaa K, Franks PW,
Hamsten A, Wichmann HE, Palmer CNA, Stefansson K, Ridker PM, Loos RJF,
Chakravarti A, Deloukas P, Morris AP, Newton-Cheh C, Munroe PB. The
genetics of blood pressure regulation and its target organs from association
studies in 342,415 individuals. Nat Genet. 2016;48:1171–1184.
23. Surendran P, Drenos F, Young R, Warren H, Cook JP, Manning AK, Grarup N,
Sim X, Barnes DR, Witkowska K, Staley JR, Tragante V, Tukiainen T, Yaghootkar
H, Masca N, Freitag DF, Ferreira T, Giannakopoulou O, Tinker A, Harakalova M,
Mihailov E, Liu C, Kraja AT, Fallgaard Nielsen S, Rasheed A, Samuel M, Zhao W,
Bonnycastle LL, Jackson AU, Narisu N, Swift AJ, Southam L, Marten J, Huyghe
JR, Stancakova A, Fava C, Ohlsson T, Matchan A, Stirrups KE, Bork-Jensen J,
Gjesing AP, Kontto J, Perola M, Shaw-Hawkins S, Havulinna AS, Zhang H,
Donnelly LA, Groves CJ, Rayner NW, Neville MJ, Robertson NR, Yiorkas AM,
Herzig KH, Kajantie E, Zhang W, Willems SM, Lannfelt L, Malerba G, Soranzo N,
Trabetti E, Verweij N, Evangelou E, Moayyeri A, Vergnaud AC, Nelson CP,
Poveda A, Varga TV, Caslake M, de Craen AJ, Trompet S, Luan J, Scott RA,
Harris SE, Liewald DC, Marioni R, Menni C, Farmaki AE, Hallmans G, Renstrom
F, Huffman JE, Hassinen M, Burgess S, Vasan RS, Felix JF; CHARGE-HF
Consortium, Uria-Nickelsen M, Malarstig A, Reily DF, Hoek M, Vogt T, Lin H,
Lieb W; EchoGen Consortium, Traylor M, Markus HF; METASTROKE
Consortium, Highland HM, Justice AE, Marouli E; GIANT Consortium, Lindstrom
J, Uusitupa M, Komulainen P, Lakka TA, Rauramaa R, Polasek O, Rudan I,
Rolandsson O, Franks PW, Dedoussis G, Spector TD; EPIC-InterAct
Consortium, Jousilahti P, Mannisto S, Deary IJ, Starr JM, Langenberg C,
Wareham NJ, Brown MJ, Dominiczak AF, Connell JM, Jukema JW, Sattar N, Ford
I, Packard CJ, Esko T, Magi R, Metspalu A, de Boer RA, van der Meer P, van der
Harst P; Lifelines Cohort Study, Gambaro G, Ingelsson E, Lind L, de Bakker PI,
Numans ME, Brandslund I, Christensen C, Petersen ER, Korpi-Hyovalti E, Oksa
H, Chambers JC, Kooner JS, Blakemore AI, Franks S, Jarvelin MR, Husemoen
LL, Linneberg A, Skaaby T, Thuesen B, Karpe F, Tuomilehto J, Doney AS, Morris
AD, Palmer CN, Holmen OL, Hveem K, Willer CJ, Tuomi T, Groop L, Karajamaki
A, Palotie A, Ripatti S, Salomaa V, Alam DS, Shafi Majumder AA, Di
Angelantonio E, Chowdhury R, McCarthy MI, Poulter N, Stanton AV, Sever P,
Amouyel P, Arveiler D, Blankenberg S, Ferrieres J, Kee F, Kuulasmaa K, Muller-
Nurasyid M, Veronesi G, Virtamo J, Deloukas P; Wellcome Trust Case Control
C, Elliott P; Understanding Society Scientific Group, Zeggini E, Kathiresan S,
Melander O, Kuusisto J, Laakso M, Padmanabhan S, Porteous D, Hayward C,
Scotland G, Collins FS, Mohlke KL, Hansen T, Pedersen O, Boehnke M,
Stringham HM; EPIC-CVD Consortium, Frossard P, Newton-Cheh C; CHARGE+
Exome Chip Blood Pressure Consortium, Tobin MD, Nordestgaard BG; T2D-
GENES Consortium; GoT2DGenes Consortium; ExomeBP Consortium; CHD
Exome+ Consortium, Caulfield MJ, Mahajan A, Morris AP, Tomaszewski M,
Samani NJ, Saleheen D, Asselbergs FW, Lindgren CM, Danesh J, Wain LV,
Butterworth AS, Howson JM, Munroe PB. Trans-ancestry meta-analyses
identify rare and common variants associated with blood pressure and
hypertension. Nat Genet. 2016;48:1151–1161.
24. Liu C, Kraja AT, Smith JA, Brody JA, Franceschini N, Bis JC, Rice K, Morrison AC,
Lu Y, Weiss S, Guo X, Palmas W, Martin LW, Chen YD, Surendran P, Drenos F,
Cook JP, Auer PL, Chu AY, Giri A, Zhao W, Jakobsdottir J, Lin LA, Stafford JM,
Amin N, Mei H, Yao J, Voorman A; Consortium CHDE, Exome BPC, Go TDC,
Consortium TDG, Larson MG, Grove ML, Smith AV, Hwang SJ, Chen H, Huan T,
Kosova G, Stitziel NO, Kathiresan S, Samani N, Schunkert H, Deloukas P;
Myocardial Infarction G, Consortia CAE, Li M, Fuchsberger C, Pattaro C, Gorski
M; Consortium CK, Kooperberg C, Papanicolaou GJ, Rossouw JE, Faul JD,
Kardia SL, Bouchard C, Raffel LJ, Uitterlinden AG, Franco OH, Vasan RS,
O’Donnell CJ, Taylor KD, Liu K, Bottinger EP, Gottesman O, Daw EW, Giulianini
F, Ganesh S, Salfati E, Harris TB, Launer LJ, Dorr M, Felix SB, Rettig R, Volzke
H, Kim E, Lee WJ, Lee IT, Sheu WH, Tsosie KS, Edwards DR, Liu Y, Correa A,
Weir DR, Volker U, Ridker PM, Boerwinkle E, Gudnason V, Reiner AP, van Duijn
CM, Borecki IB, Edwards TL, Chakravarti A, Rotter JI, Psaty BM, Loos RJ,
Fornage M, Ehret GB, Newton-Cheh C, Levy D, Chasman DI. Meta-analysis
identifies common and rare variants influencing blood pressure and overlap-
ping with metabolic trait loci. Nat Genet. 2016;48:1162–1170.
25. Hoffmann TJ, Ehret GB, Nandakumar P, Ranatunga D, Schaefer C, Kwok PY,
Iribarren C, Chakravarti A, Risch N. Genome-wide association analyses using
electronic health records identify new loci influencing blood pressure variation.
Nat Genet. 2017;49:54–64.
26. International Consortium for Blood Pressure Genome-Wide Association S,
Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, Chasman DI, Smith
AV, Tobin MD, Verwoert GC, Hwang SJ, Pihur V, Vollenweider P, O’Reilly PF,
Amin N, Bragg-Gresham JL, Teumer A, Glazer NL, Launer L, Zhao JH, Aulchenko
Y, Heath S, Sober S, Parsa A, Luan J, Arora P, Dehghan A, Zhang F, Lucas G,
Hicks AA, Jackson AU, Peden JF, Tanaka T, Wild SH, Rudan I, Igl W, Milaneschi
Y, Parker AN, Fava C, Chambers JC, Fox ER, Kumari M, Go MJ, van der Harst P,
Kao WH, Sjogren M, Vinay DG, Alexander M, Tabara Y, Shaw-Hawkins S,
DOI: 10.1161/JAHA.119.012508 Journal of the American Heart Association 10
ARMC5 and Hypertension in Blacks Zilbermint et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
Whincup PH, Liu Y, Shi G, Kuusisto J, Tayo B, Seielstad M, Sim X, Nguyen KD,
Lehtimaki T, Matullo G, Wu Y, Gaunt TR, Onland-Moret NC, Cooper MN, Platou
CG, Org E, Hardy R, Dahgam S, Palmen J, Vitart V, Braund PS, Kuznetsova T,
Uiterwaal CS, Adeyemo A, Palmas W, Campbell H, Ludwig B, Tomaszewski M,
Tzoulaki I, Palmer ND; Consortium CA, Consortium CK, KidneyGen C, EchoGen
C, Consortium C-H, Aspelund T, Garcia M, Chang YP, O’Connell JR, Steinle NI,
Grobbee DE, Arking DE, Kardia SL, Morrison AC, Hernandez D, Najjar S,
McArdle WL, Hadley D, Brown MJ, Connell JM, Hingorani AD, Day IN, Lawlor
DA, Beilby JP, Lawrence RW, Clarke R, Hopewell JC, Ongen H, Dreisbach AW, Li
Y, Young JH, Bis JC, Kahonen M, Viikari J, Adair LS, Lee NR, Chen MH, Olden M,
Pattaro C, Bolton JA, Kottgen A, Bergmann S, Mooser V, Chaturvedi N, Frayling
TM, Islam M, Jafar TH, Erdmann J, Kulkarni SR, Bornstein SR, Grassler J, Groop
L, Voight BF, Kettunen J, Howard P, Taylor A, Guarrera S, Ricceri F, Emilsson V,
Plump A, Barroso I, Khaw KT, Weder AB, Hunt SC, Sun YV, Bergman RN, Collins
FS, Bonnycastle LL, Scott LJ, Stringham HM, Peltonen L, Perola M, Vartiainen
E, Brand SM, Staessen JA, Wang TJ, Burton PR, Soler Artigas M, Dong Y,
Snieder H, Wang X, Zhu H, Lohman KK, Rudock ME, Heckbert SR, Smith NL,
Wiggins KL, Doumatey A, Shriner D, Veldre G, Viigimaa M, Kinra S,
Prabhakaran D, Tripathy V, Langefeld CD, Rosengren A, Thelle DS, Corsi
AM, Singleton A, Forrester T, Hilton G, McKenzie CA, Salako T, Iwai N, Kita Y,
Ogihara T, Ohkubo T, Okamura T, Ueshima H, Umemura S, Eyheramendy S,
Meitinger T, Wichmann HE, Cho YS, Kim HL, Lee JY, Scott J, Sehmi JS, Zhang
W, Hedblad B, Nilsson P, Smith GD, Wong A, Narisu N, Stancakova A, Raffel LJ,
Yao J, Kathiresan S, O’Donnell CJ, Schwartz SM, Ikram MA, Longstreth WT JR,
Mosley TH, Seshadri S, Shrine NR, Wain LV, Morken MA, Swift AJ, Laitinen J,
Prokopenko I, Zitting P, Cooper JA, Humphries SE, Danesh J, Rasheed A, Goel
A, Hamsten A, Watkins H, Bakker SJ, van Gilst WH, Janipalli CS, Mani KR,
Yajnik CS, Hofman A, Mattace-Raso FU, Oostra BA, Demirkan A, Isaacs A,
Rivadeneira F, Lakatta EG, Orru M, Scuteri A, Ala-Korpela M, Kangas AJ,
Lyytikainen LP, Soininen P, Tukiainen T, Wurtz P, Ong RT, Dorr M, Kroemer HK,
Volker U, Volzke H, Galan P, Hercberg S, Lathrop M, Zelenika D, Deloukas P,
Mangino M, Spector TD, Zhai G, Meschia JF, Nalls MA, Sharma P, Terzic J,
Kumar MV, Denniff M, Zukowska-Szczechowska E, Wagenknecht LE, Fowkes
FG, Charchar FJ, Schwarz PE, Hayward C, Guo X, Rotimi C, Bots ML, Brand E,
Samani NJ, Polasek O, Talmud PJ, Nyberg F, Kuh D, Laan M, Hveem K, Palmer
LJ, van der Schouw YT, Casas JP, Mohlke KL, Vineis P, Raitakari O, Ganesh SK,
Wong TY, Tai ES, Cooper RS, Laakso M, Rao DC, Harris TB, Morris RW,
Dominiczak AF, Kivimaki M, Marmot MG, Miki T, Saleheen D, Chandak GR,
Coresh J, Navis G, Salomaa V, Han BG, Zhu X, Kooner JS, Melander O, Ridker
PM, Bandinelli S, Gyllensten UB, Wright AF, Wilson JF, Ferrucci L, Farrall M,
Tuomilehto J, Pramstaller PP, Elosua R, Soranzo N, Sijbrands EJ, Altshuler D,
Loos RJ, Shuldiner AR, Gieger C, Meneton P, Uitterlinden AG, Wareham NJ,
Gudnason V, Rotter JI, Rettig R, Uda M, Strachan DP, Witteman JC, Hartikainen
AL, Beckmann JS, Boerwinkle E, Vasan RS, Boehnke M, Larson MG, Jarvelin
MR, Psaty BM, Abecasis GR, Chakravarti A, Elliott P, van Duijn CM, Newton-
Cheh C, Levy D, Caulfield MJ, Johnson T. Genetic variants in novel pathways
influence blood pressure and cardiovascular disease risk. Nature.
2011;478:103–109.
27. Wain LV, Vaez A, Jansen R, Joehanes R, van der Most PJ, Erzurumluoglu AM,
O’Reilly PF, Cabrera CP, Warren HR, Rose LM, Verwoert GC, Hottenga JJ,
Strawbridge RJ, Esko T, Arking DE, Hwang SJ, Guo X, Kutalik Z, Trompet S,
Shrine N, Teumer A, Ried JS, Bis JC, Smith AV, Amin N, Nolte IM,
Lyytikainen LP, Mahajan A, Wareham NJ, Hofer E, Joshi PK, Kristiansson K,
Traglia M, Havulinna AS, Goel A, Nalls MA, Sober S, Vuckovic D, Luan J, Del
Greco MF, Ayers KL, Marrugat J, Ruggiero D, Lopez LM, Niiranen T, Enroth
S, Jackson AU, Nelson CP, Huffman JE, Zhang W, Marten J, Gandin I, Harris
SE, Zemunik T, Lu Y, Evangelou E, Shah N, de Borst MH, Mangino M, Prins
BP, Campbell A, Li-Gao R, Chauhan G, Oldmeadow C, Abecasis G, Abedi M,
Barbieri CM, Barnes MR, Batini C, Beilby J, Blake T, Boehnke M, Bottinger
EP, Braund PS, Brown M, Brumat M, Campbell H, Chambers JC, Cocca M,
Collins F, Connell J, Cordell HJ, Damman JJ, Davies G, de Geus EJ, de
Mutsert R, Deelen J, Demirkale Y, Doney ASF, Dorr M, Farrall M, Ferreira T,
Franberg M, Gao H, Giedraitis V, Gieger C, Giulianini F, Gow AJ, Hamsten A,
Harris TB, Hofman A, Holliday EG, Hui J, Jarvelin MR, Johansson A, Johnson
AD, Jousilahti P, Jula A, Kahonen M, Kathiresan S, Khaw KT, Kolcic I,
Koskinen S, Langenberg C, Larson M, Launer LJ, Lehne B, Liewald DCM, Lin
L, Lind L, Mach F, Mamasoula C, Menni C, Mifsud B, Milaneschi Y, Morgan
A, Morris AD, Morrison AC, Munson PJ, Nandakumar P, Nguyen QT, Nutile T,
Oldehinkel AJ, Oostra BA, Org E, Padmanabhan S, Palotie A, Pare G, Pattie
A, Penninx B, Poulter N, Pramstaller PP, Raitakari OT, Ren M, Rice K, Ridker
PM, Riese H, Ripatti S, Robino A, Rotter JI, Rudan I, Saba Y, Saint Pierre A,
Sala CF, Sarin AP, Schmidt R, Scott R, Seelen MA, Shields DC, Siscovick D,
Sorice R, Stanton A, Stott DJ, Sundstrom J, Swertz M, Taylor KD, Thom S,
Tzoulaki I, Tzourio C, Uitterlinden AG, Volker U, Vollenweider P, Wild S,
Willemsen G, Wright AF, Yao J, Theriault S, Conen D, Attia J, Sever P,
Debette S, Mook-Kanamori DO, Zeggini E, Spector TD, van der Harst P,
Palmer CNA, Vergnaud AC, Loos RJF, Polasek O, Starr JM, Girotto G,
Hayward C, Kooner JS, Lindgren CM, Vitart V, Samani NJ, Tuomilehto J,
Gyllensten U, Knekt P, Deary IJ, Ciullo M, Elosua R, Keavney BD, Hicks AA,
Scott RA, Gasparini P, Laan M, Liu Y, Watkins H, Hartman CA, Salomaa V,
Toniolo D, Perola M, Wilson JF, Schmidt H, Zhao JH, Lehtimaki T, van Duijn
CM, Gudnason V, Psaty BM, Peters A, Rettig R, James A, Jukema JW,
Strachan DP, Palmas W, Metspalu A, Ingelsson E, Boomsma DI, Franco OH,
Bochud M, Newton-Cheh C, Munroe PB, Elliott P, Chasman DI, Chakravarti
A, Knight J, Morris AP, Levy D, Tobin MD, Snieder H, Caulfield MJ, Ehret GB.
Novel blood pressure locus and gene discovery using genome-wide
association study and expression data sets from blood and the kidney.
Hypertension. 2017;70:e4–e19.
28. Warren HR, Evangelou E, Cabrera CP, Gao H, Ren M, Mifsud B, Ntalla I,
Surendran P, Liu C, Cook JP, Kraja AT, Drenos F, Loh M, Verweij N, Marten J,
Karaman I, Lepe MP, O’Reilly PF, Knight J, Snieder H, Kato N, He J, Tai ES, Said
MA, Porteous D, Alver M, Poulter N, Farrall M, Gansevoort RT, Padmanabhan S,
Magi R, Stanton A, Connell J, Bakker SJ, Metspalu A, Shields DC, Thom S,
Brown M, Sever P, Esko T, Hayward C, van der Harst P, Saleheen D,
Chowdhury R, Chambers JC, Chasman DI, Chakravarti A, Newton-Cheh C,
Lindgren CM, Levy D, Kooner JS, Keavney B, Tomaszewski M, Samani NJ,
Howson JM, Tobin MD, Munroe PB, Ehret GB, Wain LV; International
Consortium of Blood Pressure (ICBP) 1000G Analyses; BIOS Consortium;
Lifelines Cohort Study; Understanding Society Scientific group; CHD Exome+
Consortium; ExomeBP Consortium; T2D-GENES Consortium; GoT2DGenes
Consortium; Cohorts for Heart and Ageing Research in Genome Epidemiology
(CHARGE) BP Exome Consortium; International Genomics of Blood Pressure
(iGEN-BP) Consortium; UK Biobank CardioMetabolic Consortium BP working
group. Genome-wide association analysis identifies novel blood pressure loci
and offers biological insights into cardiovascular risk. Nat Genet.
2017;49:403–415.
29. Duarte JD, Zineh I, Burkley B, Gong Y, Langaee TY, Turner ST, Chapman AB,
Boerwinkle E, Gums JG, Cooper-Dehoff RM, Beitelshees AL, Bailey KR, Fillingim
RB, Kone BC, Johnson JA. Effects of genetic variation in H3K79 methylation
regulatory genes on clinical blood pressure and blood pressure response to
hydrochlorothiazide. J Transl Med. 2012;10:56.
30. Kumar A, Li Y, Patil S, Jain S. A haplotype of the angiotensinogen gene is
associated with hypertension in African Americans. Clin Exp Pharmacol
Physiol. 2005;32:495–502.
31. Wen G, Wessel J, Zhou W, Ehret GB, Rao F, Stridsberg M, Mahata SK, Gent PM,
Das M, Cooper RS, Chakravarti A, Zhou H, Schork NJ, O’Connor DT, Hamilton
BA. An ancestral variant of secretogranin II confers regulation by PHOX2
transcription factors and association with hypertension. Hum Mol Genet.
2007;16:1752–1764.
32. Darlu P, Sagnier PP, Bois E. Genealogical and genetical African admixture
estimations, blood pressure and hypertension in a Caribbean community. Ann
Hum Biol. 1990;17:387–397.
33. Zhu X, Luke A, Cooper RS, Quertermous T, Hanis C, Mosley T, Gu CC, Tang H,
Rao DC, Risch N, Weder A. Admixture mapping for hypertension loci with
genome-scan markers. Nat Genet. 2005;37:177–181.
34. Ge D, Young TW, Wang X, Kapuku GK, Treiber FA, Snieder H. Heritability of
arterial stiffness in black and white American youth and young adults. Am J
Hypertens. 2007;20:1065–1072.
35. Sherva R, Miller MB, Lynch AI, Devereux RB, Rao DC, Oberman A, Hopkins PN,
Kitzman DW, Atwood LD, Arnett DK. A whole genome scan for pulse pressure/
stroke volume ratio in African Americans: the HyperGEN study. Am J
Hypertens. 2007;20:398–402.
36. Chen W, Srinivasan SR, Boerwinkle E, Berenson GS. Beta-adrenergic receptor
genes are associated with arterial stiffness in black and white adults: the
Bogalusa Heart Study. Am J Hypertens. 2007;20:1251–1257.
37. Reiner AP, Ziv E, Lind DL, Nievergelt CM, Schork NJ, Cummings SR, Phong A,
Burchard EG, Harris TB, Psaty BM, Kwok PY. Population structure, admixture,
and aging-related phenotypes in African American adults: the Cardiovascular
Health Study. Am J Hum Genet. 2005;76:463–477.
38. Tang H, Jorgenson E, Gadde M, Kardia SL, Rao DC, Zhu X, Schork NJ, Hanis CL,
Risch N. Racial admixture and its impact on BMI and blood pressure in African
and Mexican Americans. Hum Genet. 2006;119:624–633.
39. ClinicalTrials.gov. Minority health genomics and translational research bio-
repository database (MH-GRID)-2.0. 2017.
40. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott P,
Green J, Landray M, Liu B, Matthews P, Ong G, Pell J, Silman A, Young A,
Sprosen T, Peakman T, Collins R. UK Biobank: an open access resource for
identifying the causes of a wide range of complex diseases of middle and old
age. PLoS Med. 2015;12:e1001779.
41. Das S, Forer L, Schonherr S, Sidore C, Locke AE, Kwong A, Vrieze SI, Chew EY,
Levy S, McGue M, Schlessinger D, Stambolian D, Loh PR, Iacono WG, Swaroop
A, Scott LJ, Cucca F, Kronenberg F, Boehnke M, Abecasis GR, Fuchsberger C.
Next-generation genotype imputation service and methods. Nat Genet.
2016;48:1284–1287.
42. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-
generation PLINK: rising to the challenge of larger and richer datasets.
Gigascience. 2015;4:7.
43. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J,
Sklar P, de Bakker PI, Daly MJ, Sham PC. PLINK: a tool set for whole-genome
DOI: 10.1161/JAHA.119.012508 Journal of the American Heart Association 11
ARMC5 and Hypertension in Blacks Zilbermint et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
association and population-based linkage analyses. Am J Hum Genet.
2007;81:559–575.
44. Lee S, Emond MJ, Bamshad MJ, Barnes KC, Rieder MJ, Nickerson DA; Team
NGESP-ELP, Christiani DC, Wurfel MM, Lin X. Optimal unified approach for
rare-variant association testing with application to small-sample case-control
whole-exome sequencing studies. Am J Hum Genet. 2012;91:224–237.
45. Lee S, Abecasis GR, Boehnke M, Lin X. Rare-variant association analysis: study
designs and statistical tests. Am J Hum Genet. 2014;95:5–23.
46. Aschard H, Vilhjalmsson BJ, Joshi AD, Price AL, Kraft P. Adjusting for heritable
covariates can bias effect estimates in genome-wide association studies. Am J
Hum Genet. 2015;96:329–339.
47. Mefford J, Witte JS. The covariate’s dilemma. PLoS Genet. 2012;8:e1003096.
48. Pirinen M, Donnelly P, Spencer CC. Including known covariates can reduce
power to detect genetic effects in case-control studies. Nat Genet.
2012;44:848–851.
49. Berthon A, Faucz F, Bertherat J, Stratakis CA. Analysis of ARMC5 expression in
human tissues. Mol Cell Endocrinol. 2017;441:140–145.
50. Petersen A, Alvarez C, DeClaire S, Tintle NL. Assessing methods for assigning
SNPs to genes in gene-based tests of association using common variants.
PLoS One. 2013;8:e62161.
51. Davydov EV, Goode DL, Sirota M, Cooper GM, Sidow A, Batzoglou S.
Identifying a high fraction of the human genome to be under selective
constraint using GERP++. PLoS Comput Biol. 2010;6:e1001025.
52. Garber M, Guttman M, Clamp M, Zody MC, Friedman N, Xie X. Identifying novel
constrained elements by exploiting biased substitution patterns. Bioinformat-
ics. 2009;25:i54–i62.
53. Ward LD, Kellis M. HaploReg: a resource for exploring chromatin states,
conservation, and regulatory motif alterations within sets of genetically linked
variants. Nucleic Acids Res. 2012;40:D930–D934.
54. Alderman MH, Cohen HW, Sealey JE, Laragh JH. Plasma renin activity levels in
hypertensive persons: their wide range and lack of suppression in diabetic and
in most elderly patients. Am J Hypertens. 2004;17:1–7.
55. Berthon A, Stratakis CA. From beta-catenin to ARM-repeat proteins in
adrenocortical disorders. Horm Metab Res. 2014;46:889–896.
56. Tewari R, Bailes E, Bunting KA, Coates JC. Armadillo-repeat protein functions:
questions for little creatures. Trends Cell Biol. 2010;20:470–481.
57. Hu Y, Lao L, Mao J, Jin W, Luo H, Charpentier T, Qi S, Peng J, Hu B, Marcinkiewicz
MM, Lamarre A, Wu J. Armc5 deletion causes developmental defects and
compromises T-cell immune responses. Nat Commun. 2017;8:13834.
58. Berthon A, Faucz FR, Espiard S, Drougat L, Bertherat J, Stratakis CA. Age-
dependent effects of Armc5 haploinsufficiency on adrenocortical function.
Hum Mol Genet. 2017;26:3495–3507.
59. Assie G, Libe R, Espiard S, Rizk-Rabin M, Guimier A, Luscap W, Barreau O,
Lefevre L, Sibony M, Guignat L, Rodriguez S, Perlemoine K, Rene-Corail F,
Letourneur F, Trabulsi B, Poussier A, Chabbert-Buffet N, Borson-Chazot F,
Groussin L, Bertagna X, Stratakis CA, Ragazzon B, Bertherat J. ARMC5
mutations in macronodular adrenal hyperplasia with Cushing’s syndrome. N
Engl J Med. 2013;369:2105–2114.
60. Albiger NM, Regazzo D, Rubin B, Ferrara AM, Rizzati S, Taschin E, Ceccato F,
Arnaldi G, Pecori Giraldi F, Stigliano A, Cerquetti L, Grimaldi F, De Menis E,
Boscaro M, Iacobone M, Occhi G, Scaroni C. A multicenter experience on the
prevalence of ARMC5 mutations in patients with primary bilateral macron-
odular adrenal hyperplasia: from genetic characterization to clinical pheno-
type. Endocrine. 2017;55:959–968.
61. Bourdeau I, Oble S, Magne F, Levesque I, Caceres-Gorriti KY, Nolet S, Awadalla
P, Tremblay J, Hamet P, Fragoso MC, Lacroix A. ARMC5 mutations in a large
French-Canadian family with cortisol-secreting beta-adrenergic/vasopressin
responsive bilateral macronodular adrenal hyperplasia. Eur J Endocrinol.
2016;174:85–96.
62. Espiard S, Drougat L, Libe R, Assie G, Perlemoine K, Guignat L, Barrande G,
Brucker-Davis F, Doullay F, Lopez S, Sonnet E, Torremocha F, Pinsard D,
Chabbert-Buffet N, Raffin-Sanson ML, Groussin L, Borson-Chazot F, Coste J,
Bertagna X, Stratakis CA, Beuschlein F, Ragazzon B, Bertherat J. ARMC5
mutations in a large cohort of primary macronodular adrenal hyperplasia:
clinical and functional consequences. J Clin Endocrinol Metab. 2015;100:
E926–E935.
63. Faucz FR, Zilbermint M, Lodish MB, Szarek E, Trivellin G, Sinaii N, Berthon A,
Libe R, Assie G, Espiard S, Drougat L, Ragazzon B, Bertherat J, Stratakis CA.
Macronodular adrenal hyperplasia due to mutations in an armadillo repeat
containing 5 (ARMC5) gene: a clinical and genetic investigation. J Clin
Endocrinol Metab. 2014;99:E1113–E1119.
64. Correa R, Zilbermint M, Berthon A, Espiard S, Batsis M, Papadakis GZ, Xekouki
P, Lodish MB, Bertherat J, Faucz FR, Stratakis CA. The ARMC5 gene shows
extensive genetic variance in primary macronodular adrenocortical hyper-
plasia. Eur J Endocrinol. 2015;173:435–440.
65. Cavalcante IP, Nishi M, Zerbini MCN, Almeida MQ, Brondani VB, Botelho M,
Tanno FY, Srougi V, Chambo JL, Mendonca BB, Bertherat J, Lotfi CF, Fragoso
M. The role of ARMC5 in human cell cultures from nodules of primary
macronodular adrenocortical hyperplasia (PMAH). Mol Cell Endocrinol.
2018;460:36–46.
66. Mulatero P, Schiavi F, Williams TA, Monticone S, Barbon G, Opocher G, Fallo F.
ARMC5 mutation analysis in patients with primary aldosteronism and bilateral
adrenal lesions. J Hum Hypertens. 2016;30:374–378.
67. Pal JK, Chatterjee S, Rao SJ. Pathological variations in 30-untranslated regions
of human genes. eLS. 2016;1–11.
68. Vasan RS, Evans JC, Larson MG, Wilson PW, Meigs JB, Rifai N, Benjamin EJ,
Levy D. Serum aldosterone and the incidence of hypertension in nonhyper-
tensive persons. N Engl J Med. 2004;351:33–41.
69. Rayner BL, Spence JD. Hypertension in blacks: insights from Africa. J
Hypertens. 2017;35:234–239.
70. Jones ES, Spence JD, McIntyre AD, Nondi J, Gogo K, Akintunde A, Hackam
DG, Rayner BL. High frequency of variants of candidate genes in black
Africans with low renin-resistant hypertension. Am J Hypertens. 2017;30:
478–483.
71. Nanba K, Omata K, Gomez-Sanchez CE, Stratakis CA, Demidowich AP, Suzuki
M, Thompson LD, Cohen DL, Luther JM, Gellert L, Vaidya A, Barletta JA, Else T,
Giordano TJ, Tomlins SA, Rainey WE. Genetic characteristics of aldosterone-
producing adenomas in blacks. Hypertension. 2019;73:885–892.
72. Zilbermint M, Hannah-Shmouni F, Stratakis CA. Genetics of hypertension in
African Americans and others of African descent. Int J Mol Sci. 2019;20:1081.
73. Laffer CL, Elijovich F, Eckert GJ, Tu W, Pratt JH, Brown NJ. Genetic variation in
CYP4A11 and blood pressure response to mineralocorticoid receptor antag-
onism or ENaC inhibition: an exploratory pilot study in African Americans. J Am
Soc Hypertens. 2014;8:475–480.
74. Wilson TW, Grim CE. Biohistory of slavery and blood pressure differences in
blacks today. A hypothesis. Hypertension. 1991;17:I122–I128.
75. Grim CE, Robinson M. Salt, slavery and survival- hypertension in the African
diaspora. Epidemiology. 2003;14:120–122. discussion 124–126.
76. Spence JD. Hypertension in US-born vs. foreign-born African-Americans. J
Hypertens. 2017;35:2369–2371.
77. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, Collins R,
Allen NE. Comparison of sociodemographic and health-related characteristics
of UK Biobank participants with those of the general population. Am J
Epidemiol. 2017;186:1026–1034.
DOI: 10.1161/JAHA.119.012508 Journal of the American Heart Association 12
ARMC5 and Hypertension in Blacks Zilbermint et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
  
 
 
SUPPLEMENTAL MATERIAL 
 
Table S1. ARMC5 variants and risk of hypertension in African Americans: Minority Health-
GRID study. Minority Health Genomics and Translational Research Bio-Repository Database (MH-
GRID) study: inclusion and exclusion criteria. 
Inclusion Criteria 
• Self-identified African-Americans males or females ages 30-55 years. 
• Cases: Severe-Controlled Hypertension (SCH): SBP ≤ 140 and/or DBP ≤ 90 mmHg on a stable 
regimen (≥6 months) with ≥ 2 anti-hypertensive drugs (must include a diuretic). 
• Cases: Severe-Resistant Hypertension (SRH): SBP > 140 and/or DBP > 90 mmHg on a stable 
regimen (≥3 months) of ≥ 3 drugs (must include a diuretic). 
• Controls: Individuals with optimal blood pressure: ≤ 120/80 mmHg and normal kidney 
function (eGFR > 90 ml/min). 
Exclusion Criteria 
• Failure to meet the inclusion criteria. 
• Primary chronic kidney disease or proteinuria unrelated to hypertension. 
• Secondary forms of hypertension*. 
• Chronic diseases that may secondarily compromise renal function such as diabetes, chronic 
congestive heart failure, HIV or liver disease. 
• Patients with recent hospitalizations (< 3 months). 
• Unable to give informed consent. 
• Pregnant or lactating women. 
 
SBP: Systolic blood pressure, DBP: Diastolic Blood Pressure, eGFR: estimated glomerular filtration 
rate.*no aldosterone or plasma renin activity data was available 
Table S2. Gene-based analysis results, in MH-GRID. 
SNP  P-Value  Number of variants in SNP set  
Rare variants  0.0011  16 
Low frequency variants  0.1656  4  
Rare + Low frequency variants  0.0070  20  
Rare variants + rs116201073  0.0003  17  
Low frequency variants + rs116201073  0.1090  5  
Rare + Low + rs116201073  0.0057  21  
 
MH-GRID: Minority Health Genomics and Translational Research Bio-Repository Database; SNP: 
Single nucleotide polymorphisms.  
 
Table S3. Minor Allele Frequency of rs116201073, rs141923065 and rs367810854 in the 1000 
Genomes Project populations. 
Population Population  rs116201073 rs141923065 rs367810854 
African 
ACB 0.0469 0.0012 0 
ASW 0.0984 0.0052 0 
YRI 0.1019 0 0 
ESN 0.0758 0 0 
LWK 0.101 0 0 
GWD 0.1018 0 0 
MSL 0.1 0 0 
Admix 
American 
MXL 0  0 0 
PUR 0.0144 0 0 
CLM 0  0 0 
PEL 0.0059 0 0 
South Asian 
GIH 0  0 0.0631 
PJL 0  0 0.0938 
BEB 0 0 0.0581 
STU 0  0 0.0735 
ITU 0 0 0.0784 
European 
CEU 0  0 0 
TSI 0  0 0 
FIN 0  0 0 
GBR 0  0 0 
IBS 0 0 0 
East Asian 
JPT 0 0 0 
KHV 0 0 0 
CHB 0 0.0097 0 
CDX 0  0 0 
CHS 0 0 0 
ASW: African ancestry in SW USA; ACB: African Caribbean in Barbados; BEB: Bengali in 
Bangladesh; GBR: British from England and Scotland; CDX: Chinese Dai in Xishuangbanna, China; 
CLM: Colombian in Medellín, Colombia; ESN: Esan in Nigeria; FIN: Finnish in Finland; GWD: 
Gambian in Western Division – Mandinka; GIH: Gujarati Indians in Houston, Texas, United States; 
CHB: Han Chinese in Beijing, China; CHS: Han Chinese South, China; IBS: Iberian populations in 
Spain; ITU: Indian Telugu in the U.K.; JPT: Japanese in Tokyo, Japan; KHV: Kinh in Ho Chi Minh 
City, Vietnam; LWK:  Luhya in Webuye, Kenya; MS: Mende in Sierra Leone; MXL: Mexican Ancestry 
in Los Angeles CA United States; PEL: Peruvian in Lima, Peru; PUR: Puerto Rican in Puerto Rico; PJL: 
Punjabi in Lahore, Pakistan; STU: Sri Lankan Tamil in the UK; TSI: Toscani in Italy; YRI: Yoruba in 
Ibadan, Nigeria; CEU: Utah residents with Northern and Western European ancestry from the CEPH 
collection.
Figure S1. Summary of Quality Controls (QC) for MH-GRID Exome-Wide Sequencing Data. 
A. Sample QC 
 
B. Markers QC 
 
 
 
C. Principal component analysis graph after all QC show homogeneous sample set 
 
A. After excluding samples failing quality control filters 1377 samples remained for analysis. B. 44 
variants between the start and end position of the ARMC5 gene are among the 553070 variants that 
passed quality control. The Ti/Tv ratio after quality control is 3.31 indicating good quality data with 
regards to sequencing errors. C. There was no evidence of batch effect after quality control as shown by 
the homogenous cluster where the smear shape just reflects admixture from West-African to European 
ancestry shown in. 
Figure S2. Principal component analyses of MH-GRID data with 1000 Genomes Project samples. 
 
MH-GRID: Minority Health Genomics and Translational Research Bio-Repository Database; Optimal 
model is adjusted for age, sex, HDL, LDL, smoking and the first principal component (PC1) of the 
principal component analysis carried out to investigate admixture. PC1 separates the 2 continental 
ancestries relevant for this analysis. The graph represents a PCA plot of 1377 MH-GRID samples with 
eight 1000 Genome populations: 5 African, GWD (Gambian in Western Division), ESN (Esan in 
Nigeria), MSL (Mende in Sierra Leone), YRI (Yoruba in Ibadan, Nigeria) and LWK (Luhya in Webuye, 
Kenya) and 3 European, FIN (Finnish in Finland), CEU (Utah Residents with Northern and Western 
European Ancestry) and GBR(British from England and Scotland).  
Figure S3. Graphs of principal component analyses (PCA) of UK Biobank genotype data. 
 
PCA analyses of UK Biobank genotype data to determine principal components (PC)s to consider 
adjusting for ancestry. In the below figure the plots of PC1 vs. PC2 and PC2 vs. PC3 PC2 and PC3 are 
the relevant PC for the analysis restricted to the African populations (in blue). Therefore, PC2 and PC3 
were added to the model described in the manuscript. 
 
Figure S4. Comparison of wild type (WT) and mutant ARMC5 (rs116201073) expression in 
HEK293 cell line. 
 
 
 
 
 
 
Expression of wild type (WT) and mutant ARMC5 variant (rs116201073) after transfection in the 
adrenocortical cell line, H295R. The ARMC5 expression is analyzed by RTqPCR using primers 
targeting all ARMC5 isoforms (A) or only the transfected 203 isoforms (B). The graph represents the 
means of at least 2 independent experiments  SEM. 
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